Lion Point Capital’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Lion Point Capital’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-500,000	Closed	-$2.29M	–	47
2021 Q3	$2.29M	Hold	500,000	–	–	0.43%	30
2021 Q2	$2.22M	Hold	500,000	–	–	0.38%	27
2021 Q1	$3.64M	Hold	500,000	–	–	0.66%	22
2020 Q4	$3.81M	Hold	500,000	–	–	0.73%	18
2020 Q3	$4.54M	Hold	500,000	–	–	1%	17
2020 Q2	$4.23M	Hold	500,000	–	–	1.03%	19
2020 Q1	$2.47M	Hold	500,000	–	–	0.65%	21
2019 Q4	$3.6M	Hold	500,000	–	–	0.33%	22
2019 Q3	$5.41M	Hold	500,000	–	–	0.6%	20
2019 Q2	$6.5M	Hold	500,000	–	–	0.64%	22
2019 Q1	$4.94M	Hold	500,000	–	–	0.45%	19
2018 Q4	$5.2M	Buy	+500,000	New	+$6.04M	0.82%	25

Other funds holding LOGC

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

PIM

Platinum Investment Management Sydney Australia 2000, Australia $407M AUM 87.11% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

HCA

Harbor Capital Advisors Chicago, Illinois $1.47B AUM 42.58% 1-Year Est. Return

Lion Point Capital's LOGC Position: Q4 2021 in Review

Lion Point Capital sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2021, closing a stake of 500,000 shares — an estimated $2.29M sold.

Lion Point Capital first reported a position in LOGC in Q4 2018 and held it in 12 quarters. The position peaked at $6.5M in Q2 2019. 57 funds tracked by Wall St. Rank hold LOGC as of Q4 2021.

Lion Point Capital reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Lion Point Capital sold 500,000 LogicBio Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $2.29M.
Lion Point Capital first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q4 2018 and held it in 12 quarters.
Lion Point Capital's LogicBio Therapeutics, Inc. Common Stock position peaked at $6.5M in Q2 2019.
57 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Lion Point Capital's 13F filing for Q4 2021, filed 14 Feb 2022.